|
Impax in ‘Precarious Position’ as Key Products Face Competition: Analyst
Impax Laboratories’ reliance on a few key products — two generics and one brand drug — for the bulk of its revenue is likely to hurt the company in the near future as it loses its near monopoly on the drugs.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives